Insilico Medicine Shanghai Ltd., Shanghai 201203, China.
Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.
Bioorg Med Chem. 2023 Aug 15;91:117414. doi: 10.1016/j.bmc.2023.117414. Epub 2023 Jul 13.
Salt-inducible kinase 2 (SIK2) has been recognized as a potential target for anti-inflammation and anti-cancer therapy. In this paper, based on the binding pose of the reported compound (GLPG-3970, 3) with AlphaFold protein structure, a series of hinge cores were generated via AI-generative models (Chemistry42). After the molecular docking, synthesis, and biological evaluation, a hit molecule (7f) targeting SIK2 was obtained with a novel scaffold. Further SAR exploration led to the discovery of compound 8g with superior potency against SIK2 compared with the reported inhibitors. Furthermore, 8g also demonstrated excellent selectivity over other AMPK kinases, favorable in vitro ADMET profiles and decent cellular activities. This work provides an alternative approach to the discovery of novel and selective kinase inhibitors.
盐诱导激酶 2(SIK2)已被认为是抗炎和抗癌治疗的潜在靶点。在本文中,基于报道的化合物(GLPG-3970,3)与 AlphaFold 蛋白结构的结合构象,通过人工智能生成模型(Chemistry42)生成了一系列铰链核心。经过分子对接、合成和生物评价,得到了一种以新型骨架为靶点的 SIK2 命中分子(7f)。进一步的 SAR 探索导致发现了化合物 8g,其对 SIK2 的活性优于报道的抑制剂。此外,8g 对其他 AMPK 激酶也表现出优异的选择性,具有良好的体外 ADMET 特性和良好的细胞活性。这项工作为发现新型和选择性激酶抑制剂提供了一种替代方法。